Specific sites of metastases in men with metastatic castration-resistant prostate cancer (mCRPC) are associated with differential overall survival (OS), with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. This according to a study of 8,820 men with mCRPC. Researchers found:

• Most patients (72.8%) had bone with or without metastases, followed by visceral disease (20.8%), and lymph node (LN) only disease (6.4%).

• Men with liver metastases had the worst median OS (13.5 months).

• Men with lung metastases had better median OS (19.4 months) vs men with liver metastases, but significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months).

• Men with LN-only disease had median OS of 31.6 months.

• Pooled hazard ratio for death in men with lung metastases vs men with bone with or without LN metastases was 1.14.

• Pooled hazard ratio for death in men with liver metastases vs men with lung metastases was 1.52.

Citation: Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer [Published online ahead of print March 7, 2016]. Clin Oncol. doi:10.1200/JCO.2015.65.7270.